Dr Linda Malkas speaks to ecancer about her talk at AACR 2023 on AOH1996, a cancer medicine, which targets PCNA and shows promise in treating cancer patients with reoccurring solid tumours.

She outlines the background and design of the trial.

Dr Malkas explains they identified a potent PCNA inhibitor (AOH1996). The results showed AOH1996 selectively kills many types of cancer cells at below micromolar concentrations without causing significant toxicity to a broad range of nonmalignant cells.

This highlights the potential of AOH1996 as a broadspectrum therapeutic agent for the treatment of many types of cancer patients with solid tumours.